A Longitudinal Investigation of the Effects of the COVID-19 Pandemic on the Mental Health of Individuals with Pre-existing Severe Mental Illnesses
- PMID: 33038789
- PMCID: PMC7528831
- DOI: 10.1016/j.psychres.2020.113493
A Longitudinal Investigation of the Effects of the COVID-19 Pandemic on the Mental Health of Individuals with Pre-existing Severe Mental Illnesses
Abstract
Objective: Individuals with severe mental illnesses (SMI), including schizophrenia spectrum illnesses and affective disorders, may be at increased risk for negative mental health outcomes related to the COVID-19 pandemic. This study compared the severity of pre-pandemic symptoms and affective experiences to current symptoms to evaluate this possibility.
Methods: 148 individuals with SMI (92 with schizophrenia spectrum illnesses and 56 with affective disorders) were recruited from ongoing ecological momentary assessment studies that sampled day-to-day experiences and symptom severity prior to the pandemic. Participants completed a one-time phone survey that queried these same experiences/symptoms between April and June of 2020.
Results: Severity of affective experiences and psychotic symptoms remained stable across time, as did sleep duration. Well-being and the number of substances used increased during the early months of the pandemic. Increases in well-being were associated with being female and spending less time alone pre-pandemic. Patterns of stability/change did not differ according to diagnostic category.
Conclusions: At this relatively early stage, individuals with SMI are not reporting a worsening of symptoms or affective experiences and instead appear to be resilient in the face of the pandemic. Continued assessment is needed to determine whether this resilience will persist as the pandemic progresses.
Keywords: COVID-19; bipolar disorder; mood; pandemic; psychotic symptoms; schizophrenia; well-being.
Copyright © 2020 Elsevier B.V. All rights reserved.
Conflict of interest statement
Dr. Moore is a co-founder of KeyWise AI, Inc. and a consultant for NeuroUX. Dr. Harvey has received consulting fees or travel reimbursements from Acadia Pharma, Alkermes, Bio Excel, Boehringer Ingelheim, Minerva Pharma, Otsuka Pharma, Regeneron Pharma, Roche Pharma, and Sunovion Pharma during the past year. He receives royalties from the Brief Assessment of Cognition in Schizophrenia. He is chief scientific officer of i-Function, Inc. He had a research grant from Takeda and from the Stanley Medical Research Foundation. No other authors have conflicts of interest to report.
References
-
- Amador X.F., Strauss D.H., Yale S.A., Flaum M.M., Endicott J., Gorman J.M. Assessment of insight in psychosis. American journal of Psychiatry. 1993;150 873-873. - PubMed
-
- Choi K.R., Heilemann M.V., Fauer A., Mead M. A second pandemic: Mental health spillover from the novel coronavirus (COVID-19) Journal of the American Psychiatric Nurses Association. 2020 - PubMed
-
- First M.B., Williams J.B.W., Karg R.S., Spitzer R.L. Structured clinical interview for DSM-5—Research version (SCID-5 for DSM-5, research version; SCID-5-RV) American Psychiatric Association, Arlington VA. 2015
-
- Fitzpatrick K.M., Harris C., Drawve G. Fear of COVID-19 and the mental health consequences in America. Psychological Trauma: Theory, Research, Practice, and Policy. 2020 - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
